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INTRODUCTION 
 
         Health aspects in postmenopausal women have gained importance in recent 
years owing to the increased life expectancy. According to WHO, the disability 
adjusted life expectancy (DALE) exceeds 70 yrs in about 24 countries, with 
women living longer than men by an average of 7 to 8 years (1). The average age 
at menopause ranges from 45 yrs in the Indian woman to 51 years in the Western 
population depending on the hereditary, life style and nutritional factors (2, 3, 
4).Thus a woman spends more than two to three decades of life in her menopause.  
          The principal gynecological cancers (breast, ovary, uterus, and cervix) 
account for over 40% of cancers found in women worldwide. However, large 
differences exist, in both their incidence and geographical distribution. 
Endometrial cancer is currently the most common gynecological malignancy in 
developed countries (5). A number of reports have suggested that the incidence of 
carcinoma of the endometrium is increasing in the United States and other 
industrialised countries (6, 7). The incidence of endometrial cancer is 3.7% to 
17.9% in postmenopausal women with abnormal uterine bleeding (8, 9). The 
incidence of endometrial cancer in asymptomatic women was 0.13% and atypia 
was seen in 0.63% (10). 
             Endometrial carcinoma fortunately when detected early can be cured with 
less morbidity and mortality. It has much higher cure rates if diagnosed early. 
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Localised disease(stage I and II) has a 5 year survival of 87% and 76% 
respectively, but much poorer for stage III with 5 yr survival rate of <60% 
(11).Endometrial polyps often have hyperplastic changes and the risk of 
premalignant to malignant polyp increases with age, menopausal status and 
hypertension (12). In contrast to cervical cancer, there are no routine mass 
screening programmes for the early detection of endometrial abnormalities.  
 Tradionally dilatation and curettage has been used for endometrial sampling. 
Dilation and curettage is invasive, and is associated with a 1–2% complication 
rate, thus less invasive endometrial biopsy techniques are increasingly favoured 
for evaluating these women (13). Although many safe techniques are now 
available for detecting and diagnosing neoplastic lesions of the endometrium, 
these methods are invasive (14, 15). It might be preferable to first use some 
noninvasive method, such as ultrasound, to identify women at risk who should 
undergo endometrial biopsy. 
              Transabdominal sonography can be used to detect many forms of 
endometrial pathology including cancer. Transvaginal sonography yields even 
more detailed images of the uterus (16, 17). It facilitates the measurement of 
endometrial thickness and morphology with good patient acceptance. Transvaginal 
sonography measurement of endometrial thickness and morphology has been 
demonstrated to have high accuracy in excluding endometrial polyps, hyperplasia 
and cancer in women with post menopausal bleeding (18).It is minimally invasive 
and has high cancer detection rates (19,20). In populations with 31% or less 
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combined prevalence of endometrial carcinoma or atypical adenomatous 
hyperplasia, algorithms utilizing transvaginal sonography as the initial test are 
most cost effective when compared to biopsy-based algorithms in evaluating 
perimenopausal and postmenopausal women with abnormal vaginal bleeding (21). 
The society of Radiologists in Ultrasound sponsored Consensus Conference 
statement state that in the evaluation of women with PMB either transvaginal 
sonography or endometrial biopsy could be used safely and effectively as the first 
diagnostic step (23). 
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REVIEW OF LITERATURE   
 
            Menopause is the permanent cessation of menstruation. It is defined 
retrospectively as the time of the final menstrual period followed by 12 months of 
amenorrhea. Post menopause describes the period following the final menses (3). 
Postmenopausal bleeding describes the occurrence of vaginal bleeding following a 
woman’s last menstrual cycle irrespective of the quantity of bleeding. Vaginal 
bleeding that occurs after 6 months of amenorrhea from presumed menopause 
should be considered abnormal (24). 
           Post menopausal bleeding is a serious complaint. It is the most common 
clinical symptom of endometrial carcinoma. About 10 to 20% of all women with 
postmenopausal bleeding are diagnosed with endometrial carcinoma and hence all 
women require investigation to exclude malignancy (26). 
 
Causes of postmenopausal bleeding 
[Weiderpass et al (25)] 
Normal or atrophic 58.8% 
Endometrial carcinoma 9.4% 
Endometrial polyp 9.4% 
Carcinoma of cervix 6% 
Submucous fibroid 4% 
Endometrial hyperplasia, pyometra, 
ovarian cancer, urethral caruncle  
12.4% 
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 Endometrial Carcinoma   
 
         Endometrial carcinoma is primarily a disease of postmenopausal women 
with the peak incidence at the age of 55-65 years. Adenocarcinoma accounts 
for > 80% of endometrial cancers. Other types include papillary serous, clear cell, 
squamous, mucinous carcinoma, and sarcomas. Staging is based on histologic 
differentiation -grade 1 (least aggressive) to grade 3 (most aggressive) and extent 
of spread, including invasion depth, cervical involvement -glandular involvement 
versus stromal invasion, and extrauterine metastases. Endometrial carcinoma has 
been classified into 2 groups on the basis of pathogenetic factors. 
 
Type 1 carcinoma 
It accounts for about 75% to 85% of the carcinoma and arises from often with a 
history of unopposed estrogen exposure or hyperplastic endometrium. Type I is so 
called estrogen-dependent, which appears mostly in pre- and perimenopausal 
women. It is usually of the low-grade endometrioid type, and carries a good 
prognosis. 
 
Type 2 carcinoma 
It occurs in the background of atrophic endometrium (3). Type 2 carcinoma is 
estrogen independent, diagnosed mostly in postmenopausal women. It is often 
high grade tumor with poor prognosis.  
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There are several risk factors associated with endometrial hyperplasia and 
carcinoma.  
 
 Risk factors for endometrial carcinoma :( 3, 27) 
• Early menarche <10 yrs 
• Late menopause >55 yrs 
• Nulliparity 
• Unopposed estrogen therapy 
• Obesity 
• Diabetes 
• Liver disease 
• Persistent / Recurrent bleeding 
• Hypertension 
• Atypical hyperplasia 
• Tamoxifen therapy   
• HNPCC syndrome 
 
 7
Endometrial hyperplasia 
 
       Endometrial hyperplasia is defined as an increase in the glandular to stromal 
tissue ratio to more than one (3). Endometrial hyperplasia which increases the risk 
of endometrial carcinoma, comprises a wide spectrum of histological changes 
from simple aggregation of the normal-looking proliferate glands at one extreme 
to the changes that are difficult to distinguish from carcinoma at the other end of 
the spectrum. Endometrial hyperplasia is clinically important because they may 
cause abnormal bleeding, result from hormonal therapy or precede or occur 
simultaneously with endometrial cancer. Most cases of endometrial hyperplasia 
result from high levels of estrogens, combined with insufficient levels of 
the progesterone hormones which counteract estrogen's proliferative effects on the 
endometrium. 
         Not only does the concern exist for atypical hyperplasia progressing to 
invasive cancer, but numerous studies found concurrent carcinoma at rates ranging 
from 17-52%. Part of the difficulty in diagnosing concurrent carcinoma is due to 
lack of reproducibility in diagnosing hyperplasia, especially atypical hyperplasia 
versus carcinoma. 
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Type of hyperplasia and progression to carcinoma 
[Kurman et al (28]) 
Type of hyperplasia Progression to cancer (%) 
Simple(cystic without atypia) 1 
Complex (adenomatous without 
atypia) 
3 
Simple(cystic with atypia) 8 
Complex(adenomatous with atypia) 29 
 
Endometrial polyp 
 
     Endometrial polyps are localized hyperplastic overgrowths of endometrial 
glands and stroma around a vascular core that form a sessile or pedunculated 
projection from the surface of the endometrium. Single or multiple polyps can 
occur that range from a few millimeters to several centimeters in size. Endometrial 
polyps are rare among women younger than 20 years of age. The incidence rises 
steadily with increasing age, peaks in the fifth decade of life, and gradually 
declines after menopause. Women with Hereditary Nonpolyposis Colon Cancer 
syndromes may have an increased incidence of endometrial polyps with malignant 
changes compared to the general population. Large endometrial polyps can also be 
associated with tamoxifen use. These polyps are associated with a higher risk of 
neoplasia. 
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      Endometrial intraepithelial neoplasia (EIN) is a precursor to endometrioid 
endometrial adenocarcinoma characterized by monoclonal growth of mutated 
cells, a distinctive histopathologic appearance, and 45-fold elevated cancer risk 
(29). EIN within polyps are best recognized as geographic regions of contiguous 
glands with an architecture and cytology readily distinguished from that of the 
background polyp. EIN features are more commonly seen in endometrial polyps 
with metaplastic changes (30). 
 
  Endometrial atrophy 
 
        Endometrial atrophy describes the loss of glandular and stromal elements of 
the endometrium and arises following the withdrawal of endogenous ovarian 
steroids. Endometrial atrophy is the most common cause of abnormal 
postmenopausal bleeding. It usually occurs after a considerable number of years 
after menopause. The thin atrophic endometrium in postmenopausal women is 
prone to superficial ulceration that can lead to bleeding. The functional layer of 
endometrium is difficult or impossible to separate from the basalis. Tissue biopsy 
from atrophic endometrium is sparsely cellular and is often inadequate. 
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Investigation modalities 
 
  Imaging techniques of the endometrium 
 
• Transabdominal ultrasonography(TAS) 
• Trasvaginal ultrasonography(TVS) 
• Ultrasound with Colour Doppler imaging 
• Saline infusion sonohysterography(SIS) 
• Computed Tomography(CT) 
• Magnetic Resonance Imaging(MRI) 
 
Transabdominal ultrasonography  
 
            TAS is performed through subcutaneous fat and abdominal wall muscles 
and uses the full urinary bladder as an acoustic window. In gynaecology the 
frequency of probes range from 3 to 5 MHz.It is used as the first line investigation 
in most of the gynaecological work up of the disease and for follow up. 
 
Advantages 
 Non invasive 
 Wide field of view 
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 Suitable for all ages 
 Suitable for large masses 
 Chaperone not required 
 Easy availability 
Disadvantages 
 Poor resolution due to low probe frequency 
 Requires full bladder 
 Bowel gases may obscure the view 
 Observer dependent 
 Images affected by maternal habitus 
 
Transvaginal ultrasound 
 
           TVS is now being extensively used in the Obstetrics and Gynaecology for 
imaging of pelvic pathology. Gynecologic transvaginal ultrasound uses a 
transducer placed in the vaginal part of a woman. This transducer is made up of 
special shape that can fit into vagina. It uses a probe frequency of 5 to 8 MHz. 
Transvaginal ultrasound technique allows placement of high frequency probe 
close to target pelvic organs to demonstrate anatomic detail not duplicated by 
transabdominal approach. Pelvic ultrasound evaluates the bladder, ovaries, uterus, 
cervix, fallopian tubes. 
 
 
 
 
 
TRANSVAGINAL ULTRASOUND 
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 Uses in Gynaecology 
 To assess pelvic organs. 
 To diagnose and manage gynecologic problems including endometriosis, 
leimyoma, adenomyosis, ovarian cysts. 
 In perimenopausal and postmenopausal bleeding. 
 To identify ovarian growth and other adnexal masses. 
 In the screening and diagnosis of gynaecological cancer. 
 In infertility treatments. 
 Detect the cause of pelvic pain. 
 Observe for the pelvic inflammatory disease. 
 Check for intrauterine device (IUD). 
Advantages 
 Increased resolution in imaging the pelvic organs due to high probe 
frequency and proximity to the organs. 
 Empty bladder. 
 Not dependent on maternal habitus. 
 Superior to CT and equivalent to MRI regarding myometrial, cervical and 
parametrial involvement in carcinoma endometrium. 
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Disadvantages 
 Internal examination 
 Cannot be used in all ages 
 Operator dependent 
 Chaperone required 
 Possible discomfort 
 
Normal findings of the endometrium (31) 
 
- Paediatric endometrium:thin,echogenic line 
- During menstruation: thin, echogenic line 1–4 mm in thickness 
- Proliferative phase: 5-7 mm, echogenic 
- Ovulatory endometrium: upto 11 mm thick, trilaminar appearance 
- Secretory phase: 7-16 mm , echogenic 
- Postmenopausal endometrium: Thin, homogenous,echogenic line less than  
5 mm 
 
Abnormal findings of the endometrium (31, 32) 
 
-Endometrial polyp: Focal homogenous endometrial thickening. 
-Endometrial hyperplasia: Uniform, diffuse thickening, echogenic.  
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-Endometrial carcinoma: Thick, echogenic, heterogenous, endometrial myometrial 
interface irregular, loss of endometrial halo. 
-Submucosal fibroid- hypoechoic, solid mass with distortion of uterine cavity 
-Tamoxifen induced changes: Thickening associated with sub endometrial cysts 
 
Doppler imaging 
 
 The value of Doppler and color Doppler US in distinguishing benign from 
malignant endometrial disease is controversial.  Significant overlap in Doppler 
indices (ie, peak systolic velocity, resistive index, pulsatility index) in benign and 
malignant endometrial processes reduces the value of Doppler US in 
characterizing endometrial masses. Color and power Doppler US may 
occasionally aid in determining the presence and extent of tumor invasion and 
ensuring that biopsies are directed toward regions with increased blood flow (33). 
 
Saline infusion sonohysterography 
 
Trans vaginal ultrasonography immediately following instillation of 10 ml saline 
in the uterine cavity provides excellent visualization of the endometrium. Polyps 
are best seen at sonohysterography and appear as echogenic, smooth, intracavitary 
masses outlined by fluid (34). Sonohysterography with 93% sensitivity, 56% 
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specificity, 86% PPV, and 71% NPV is considered better for diagnosing focal 
intrauterine lesion (53). 
 
CT/MRI 
 
CT and MRI are more accurate staging modalities than ultrasound. Both 
techniques allow survey of the entire pelvis, abdomen, thorax, and brain. They are 
more superior in detecting enlarged abdominal or pelvic lymph nodes and in 
depicting intraperitoneal, omental, or mesenteric metastases. MRI has 76% 
sensitivity and 92% specificity (52). In addition, USG is inferior to CT in 
assessing pelvic sidewall extension and adjacent organ invasion but USG is cost 
effective with easy availability.  
 
Endometrial sampling techniques 
 
 Pap smear 
 Aspiration cytology 
 Dilatation and curettage 
 Hysteroscopy guided biopsy 
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Pap smear 
 
- It is primarily used as a screening test for preinvasive and early invasive 
cervical carcinoma. 
- It is a noninvasive and cost-effective test but it is inadequate and insensitive to 
be used as a screening test or diagnostic test for endometrial diseases (35). 
- Only 50% of the endometrial cancer is present are positive for (glandular) 
cancer cells. This is not a high enough percentage to be used as the primary 
diagnostic test. 
 
Aspiration cytology 
 
- It is used as one of the first line investigations of postmenopausal bleeding. 
- Various models are available like the Vabra aspirator, Pipelle aspiration etc. 
- Advantages are that they out patient procedure and cost effective. 
- The sensitivity of the procedure is 81.63% and the specificity is 83.33%.(54) 
- Major limitations are they are invasive, small focus are missed, a risk of 
uterine perforation and inability to sample in cervical stenosis. 
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Dilatation & curettage 
 
-Introduced in 1943 and been used since for endometrial sampling. 
-Only less than half of the uterine surface is sampled and the probability of 
missing the diagnosis is 10-25% and fails to diagnose 70% of all focal 
intracavitary lesions. 
-  The sensitivity, specificity, PPV, and NPV of dilation and curettage were 47, 68, 
57 and 59%, respectively. (53) 
-It is being replaced by other modalities due to the blind nature of the procedure, 
invasive, risk of uterine perforation and infection, need for anesthesia, and 
inadequate sampling (36). 
 
Hysteroscopy 
 
- Hysteroscopy is considered the gold standard investigation in abnormal uterine      
      bleeding. 
-    Hysteroscopy has sensitivity and specificity of 84% and 88% respectively (52). 
- It is the inspection of the uterine cavity by endoscope. It allows for the 
diagnosis of intrauterine pathology and serves as a method for surgical 
intervention. 
- It allows direct visualisation of the uterine cavity enabling guided biopsy, 
without cervical dilatation and could be done as a office procedure 
-   Disadvantages are the cost of instruments, operator expertise and risk of uterine  
     perforation. 
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Contemporary studies 
 1. Transvaginal ultrasonography of the endometrium in postmenopausal     
      Japanese women (37). 
        The aim of the study was to determine the cut-off level of endometrial 
thickness for detecting endometrial disease on a large scale of screening 
and to examine the usefulness of TVS for screening endometrial disease in 
postmenopausal Japanese women. The study involved a total of 1,400 
women in whom TVS was performed and then compared with 
histopathological specimen. The prevalence of endometrial disease was 
seen in 2.3% of asymptomatic and 21% of symptomatic women. A 3 mm 
cut off has 94% sensitivity, 70 specificity and 46% PPV in detecting 
endometrial disease in symptomatic cases. In asymptomatic cases for a 
similar cut off the values were 90%, 84%, 12% respectively. They 
concluded that TVS did not appear to be an effective screening method in 
asymptomatic postmenopausal women. They recommend a 4 mm cut off 
level in symptomatic Japanese women as normal.  
2. Transvaginal sonography of the endometrium in a representative  
       sample of postmenopausal women (38).  
        The aim of the study of the study was to assess the endometrial 
thickness using TVS in a representative sample of postmenopausal women 
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and to evaluate whether the technique can be used for screening of 
endometrial carcinoma. A random sample of total population was invited 
for the study of which 827 women in the age 45-80 years were screened. 
The only exclusion criterion was hysterectomy.   Endometrial thickness of 
less than 4 mm was not investigated further. Women with endometrial 
thickness of 5-7 mm and non measurable cases were reassessed 1 year later 
and if ≥ 8 mm were investigated directly.33% of the women were on some 
form of hormone substitution. The endometrial thickness was grouped into 
≤ 4 mm, 5-7 mm and ≥ 8mm. In postmenopausal women not on estrogens 
the thickness seen were 90%, 7% and 3%; on medium potency estrogens 
49%, 40% and 11%; on low potency estrogens 85%,6%, and 9% 
respectively. The prevalence of endometrial carcinoma was 0.2% and for 
benign polyps 3.2% and no cases of endometrial hyperplasia were reported. 
The authors concluded that the results do not support TVS for generalised 
screening for endometrium.  
3.  Transvaginal sonography of the endometrium in  south Indian  
  postmenopausal women (39). 
        The aim of the study was to compare the transvaginal sonographically-
measured endometrial thickness with the histopathological diagnosis in 
postmenopausal women. Eighty postmenopausal women were studied 
prospectively. All of them underwent transvaginal sonography followed by 
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either an office dilatation and curettage or a hysterectomy. Eight women 
had endometrial carcinoma and their mean endometrial thickness was 
12.6±5 mm. Taking 4 mm endometrial thickness as cut off the sensitivity of 
transvaginal scan to detect endometrial pathology was 97%, specificity 
98%, positive predictive value 97% and negative predictive value 94%. 
They concluded that measurement of endometrial thickness by transvaginal 
scan is a good screening test in postmenopausal women for differentiating 
endometrial pathology from those who do not have an endometrial lesion 
 
4. Transvaginal ultrasonography of the endometrium in women with          
      postmenopausal bleeding: is it always necessary to perform an  
      endometrial biopsy? (40) 
          This study was undertaken to evaluate whether it was possible to 
abstain from performing an endometrial biopsy when endometrial thickness 
according to transvaginal ultrasonography was ≤ 4 mm in women with 
postmenopausal bleeding or irregular bleeding during hormone replacement 
therapy. A total of 361 women were involved in the study. They were 
reexamined at 4 and 12 months if endometrium was ≤ 4mm or endometrial 
biopsy was performed if ≥ 5 mm. They were also instructed to return if they 
had recurrent bleeding, in which case transvaginal ultrasonography was 
performed and an endometrial biopsy specimen was obtained. Endometrial 
malignancy was diagnosed in 0.6% of the women with an endometrial 
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thickness ≤ 4 mm. Endometrial biopsy was performed because of recurrent 
bleeding in 6.1% of cases and because of endometrial thickening in 8.1%. 
No cancer or hyperplasia was subsequently diagnosed among the women 
with an endometrial thickness ≤ 4 mm. Endometrial cancer was diagnosed 
in 18.7% of the women with an endometrial thickness ≥ 5 mm.  They 
concluded that a  transvaginal ultrasonography and or a cervical cytologic 
examination is an adequate form of management for women with 
postmenopausal bleeding or irregular bleeding during hormone replacement 
therapy as long as endometrial thickness is ≤ 4 mm 
5. Can ultrasound replace dilatation and curettage? A longitudinal  
      evaluation of postmenopausal bleeding and transvaginal sonographic  
     measurement of the endometrium as predictors of endometrial  
     cancer (41). 
The study purpose was to evaluate postmenopausal bleeding and TVS 
measurements of endometrial thickness as predictors of endometrial cancer 
and atypical hyperplasia in women whose cases were followed up for ≥ 10 
years after referral for postmenopausal bleeding. Of the 394 patients, it was 
possible to obtain records of 339 women. Thirty-nine of 339 women 
(11.5%) had endometrial cancer, and 5 women (1.5%) had atypical 
hyperplasia. The relative risk of endometrial cancer in women who were 
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referred for postmenopausal bleeding was 63.9; the corresponding relative 
risk for endometrial cancer and atypical hyperplasia together was 72.1 
compared with women of the same age from the general population. No 
woman with an endometrial thickness of ≤ 4 mm was diagnosed as having 
endometrial cancer. The relative risk of the development of endometrial 
cancer in women with an endometrial thickness of > 4 mm was 44.5 
compared with women with an endometrial thickness of ≤ 4 mm. The 
reliability of endometrial thickness (cutoff value, ≤ 4 mm) as a diagnostic 
test for endometrial cancer was assessed: Sensitivity, 100%; specificity, 
60%; positive predictive value, 25%; and negative predictive value, 100%. 
No endometrial cancer was diagnosed in women with a recurrent 
postmenopausal bleeding who had an endometrial thickness of ≤ 4 mm at 
the initial scan. The authors conclude that postmenopausal bleeding incurs 
a 64-fold increase risk for endometrial cancer. There was no increased risk 
of endometrial cancer or atypia in women who did not have recurrent 
bleeding, whereas women with recurrent bleeding were a high-risk group. 
No endometrial cancer was missed when endometrial thickness 
measurement (cutoff value, ≤ 4 mm) was used, even if the women were 
followed up for ≤ 10 years. We conclude that transvaginal sonographic 
scanning is an excellent tool for the determination of whether further 
investigation with curettage or some form of endometrial biopsy is 
necessary. 
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6. Gray-scale ultrasound morphology in the presence or absence of  
      intrauterine fluid and vascularity as assessed by color Doppler for  
      discrimination between benign and malignant endometrium in women  
      with postmenopausal bleeding (42). 
The objective was to determine if gray-scale ultrasound morphology in the 
presence or absence of intrauterine fluid and endometrial vascular 
morphology by colour Doppler USG can discriminate between benign and 
malignant endometrium in women with postmenopausal bleeding. 95 
women with postmenopausal bleeding and endometrial thickness > or = 4.5 
mm were included. There were no statistically significant differences in 
ultrasound findings between benign and malignant endometria of uterine 
cavities without fluid. The sensitivity, false positive rate, positive and 
negative likelihood ratios of the morphlogical findings were as follows: 
heterogeneous echogenicity, 80%, 29%, 2.74, 0.28; irregular surface, 89%, 
33%, 2.70, 0.17; and both, 78%, 12%, 6.59, 0.25. There was no 
significance associated with fluid in the endometrial cavity.  The authors 
concluded that heterogeneous echogenicity and an irregular surface of a 
focal lesion or of the endometrium are useful ultrasound criteria for 
predicting endometrial malignancy. Assessment of vascular morphology 
using color Doppler ultrasound is of limited value for discrimination 
between benign and malignant endometrium. 
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AIM OF THE STUDY 
 
1) To evaluate the role of transvaginal ultrasonography in evaluating endometrial  
     pathology in postmenopausal women using endometrial thickness  
     measurements and morphological changes within the endometrium to define  
     abnormality and able to choose the technique of biopsy if needed. 
  
2) To assess the utility of TVS as a routine screening tool in detecting endometrial  
     disease in all postmenopausal women.   
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MATERIALS AND METHODS 
 
A total of 105 postmenpausal women who attended the Gynaecology outpatient 
department at the Institute of Obstetrics and Gynecology from April 2008 to 
September 2009 were screened for this study. 
 
The women were selected based on the inclusion and exclusion criteria. 
 
Inclusion criteria 
 
-    Last menstrual cycle at least one year back (Menopausal women). 
- All patients with complaints of post menopausal bleeding. 
- Endometrial thickness more than 5 mm in asymptomatic women. 
- Age 40 years and above. 
- Not on any hormonal treatment. 
- Absence of other pelvic diseases and blood dyscrasis. 
 
Exclusion criteria 
 
- Carcinoma cervix. 
- Other pelvic pathologies or blood dyscrasis. 
- Hormonal treatment. 
- Endometrial thickness less than 5 mm in asymptomatic women. 
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The subject is asked to empty the bladder before the examination. A small amount 
of gel is applied over the transducer tip and the probe is covered by a condom. A 
small amount of lubricant gel is applied over the probe to allow easy insertion. 
Transvaginal transducer of 5.5 to 8.5 MHz  was used. 
 
 The endometrim was imaged in the sagittal plane. 
 Both layers of the endometrium were measured that is the anterior 
and the posterior layers. 
 The thickest point of the endometrium was measured from the 
anterior to posterior myometrial-endometrial junction. 
 If there was fluid in the cavity each layer was measured separately 
and summed up. 
 Morphological changes were determined by irregular endometrium, 
heterogeneous echo texture, focal thickening and indistinct 
endometrial borders. 
 The presence of endometrial halo (hypoechoic area between the 
endometrium and inner myometrium) was noted. 
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Transvaginal ultrasonography diagnosis was given as 
 
• Atrophic: Thin line, homogenous, endometrial thickness <5mm. 
• Thickened: homogenous, regular margins, endometrial thickness 
<10mm with no features suggestive of any abnormality. 
• Endometrial polyp: Focal homogenous endometrial thickening, 
regular margins. 
• Endometrial hyperplasia: Uniform, diffuse thickening, 
echogenic, endometrial thickness >10 mm or <10 mm thickness 
when features suggestive of  hyperplasia present 
• Endometrial carcinoma: Thick, echogenic, heterogenous, 
irregular endometrial myometrial interface, loss of endometrial 
halo. 
 
Histopatholgical diagnosis of the endometrium was obtained from 
specimens obtained by dilatation and curettage or operative 
hysteroscopy guided biopsy or by hysterectomy. The histopathology of 
the endometrium was considered gold standard. 
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RESULTS 
In this prospective descriptive study, 
105 postmenopausal women were involved in the study and outcome analysed 
using various parameters. The results were statistically analyzed using Chi-square 
test and frequency and percentage analysis 
Sample size- 105 
TVS performed in 105 
Histopathological diagnosis obtained in 105 
 
DISTRIBUTION PARAMETERS: 
Table 1: Age distribution 
Age (yrs) No. % 
41-45 14 13.3 
46-50 34 32.4 
51-55  29 27.6 
56-60  19 18.1 
>60 9 8.6 
Total 105 100 
 
Majority of the women belong to the age group 46-50 yrs (32.4%). 
The mean age of distribution: 52.9 yrs. 
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Table 2: Parity distribution 
      Parity No. % 
0 4 3.8 
   I 6 5.7 
   II 17 16.2 
   III 33 31.4 
   IV 25 23.8 
   V and above 20 19 
Total 105 100 
 
Women of all parity were included. 
Majority of the women were had 3 or more parous pregnancies (74.28%). 
 
Table 3: Distribution of years of menopause 
Yrs of menopause No. % 
1-5 62 59 
6-10  24 22.9 
11-15  10 9.5 
>15  9 8.6 
Total 105 100 
 
Most of the women had attained menopause within 1 to 5 years. 
The mean number of years in menopause was 6.2 years. 
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Table 4: Distribution of associated diseases 
Associated diseases No. % 
Obesity 25 23.8 
Diabetes mellitus 6 5.7 
Hypertension 5 4.76 
Hypertension & Diabetes 
mellitus  
2 1.9 
Obesity& HT 10 9.52 
Obesity & DM 4 3.8 
HT &DM &Obesity 2 1.9 
Carcinoma caecum 1 0.95 
Carcinoma breast 1 0.95 
Anaemia 1 0.95 
 
Of the 105 women screened, 32 women (30.5%) had co morbid diseases. 
37.1% (39/105) were obese (obesity was determined as BMI >30). 
Hypertension was the most common co morbid condition seen in 19 women .Of 
these 10 of them were obese, 2 had associated diabetes mellitus and 2 were 
diabetic and obese. 
There were 2 women with prior carcinoma, treated and on follow up. 
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Table 5: Distribution of complaints (post menopausal bleeding) 
PMB No. % 
Yes 70 66.67 
No 35 33.33 
Total 105 100 
 
70 women had postmenopausal bleeding and 35 women were asymptomatic of the 
105 women screened representing 66.6% and 33.3% of the study group 
respectively. 
 
Table 6: Distribution of findings in TVS of endometrium 
TVS findings No. % 
Atrophic  31 29.6 
Thickened 50 47.62 
Hyperplasia 13 12.38 
Carcinoma  8 7.6 
Polyp 3 2.8 
Total 105 100 
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Of the subjects screened the TVS findings determined were:  
Atrophic and thickened endometria were considered normal findings which was 
81 of 105 (77.1%).  
The following were considered abnormal seen in 22.9% (24/105) 
Endometrial hyperplasia was seen in 13 of 105 women (12.3%), endometrial 
carcinoma in 8 women (7.62%) and endometrial polyp in 3 women (2.8%). 
 
Table 7: Distribution of findings in histopathology of endometrium 
Histopathology No. % 
Atrophic  50 47.62 
Proliferative / Secretory 35 33.33 
Hyperplasia 9 8.57 
Carcinoma 7 6.66 
Polyp 4 3.8 
Total 105 100 
 
The histopathological diagnosis was considered gold standard. 
The following were considered normal finding seen in 85/105(81%) of all 
women. 
Atrophy of endometrium seen in 47.6%, secretory and proliferative 
endometrium seen in 33.3%. 
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Abnormal findings were Endometrial Hyperplasia in diagnosed in  
9 women, endometrial carcinoma in 7 women and endometrial polyp in  
4 women. 
Abnormal findings constituted 20/105 (19%) of the study population. 
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GENERAL PARAMETERS 
 
Table 8: Comparison of age with histopathology 
HPE
 
AGE (yrs) 
Normal 
 
Abnormal 
 
Total 
≤50  43 5 48 
51-55  23 6 29 
56-60  12 7 19 
>60  7 2 9 
Total 85 20 105 
 
P value-0.097 – not significant 
There was no statistically significant difference in the age of the patient and the 
presence of endometrial disease. 
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Table 9: Comparison of years of menopause with histopathology 
HPE
Yrs of menopause 
Normal Abnormal Total 
1- 5  53 9 62 
6- 10  21 3 24 
11-15  5 5 10 
>15  6 3 9 
Total 85 20 105 
 
P value-0.031, significant 
There was statistically significant difference between the total number of years 
after menopause and endometrial disease. 
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Table 10: Comparison of co-morbid disease with histopathology 
HPE
Disease distribution 
Normal Abnormal Total 
Diabetes 7 3 10 
Hypertension 9 6 15 
Diabetes & Hypertension 1 3 4 
Other carcinoma 0 2 2 
Nil  68 6 74 
Total 85 20 105 
 
P value- 0.0, significant 
There is significant difference in the ‘P’ value between hypertension, diabetes, and 
carcinoma of breast and caecum with endometrial disease. 
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Table11: Comparison of BMI with histopathology 
HPE  
BMI 
Normal Abnormal Total 
<30 57 9 66 
≥30 28 11 39 
Total 85 20 105 
 
P value-0.066, not significant 
There is no statistically significant difference in women who are obese and 
endometrial disease. 
 
Table 12: Comparison of post menopausal bleeding with histopathology 
HPE  
PMB 
Normal Abnormal Total 
Present 52 18 70 
Absent 33 2 35 
Total 85 20 105 
 
P value-0.14, significant 
There is significant association between PMB and endometrial disease. 
Endometrial disease is present more in women with postmenopausal bleeding than 
those without bleeding. 
  
38
TVS PARAMETERS 
 
Table 13: Comparison of appearance of endometrium with histopathology 
HPE 
Appearance 
Normal Abnormal Total 
Homogenous 84 12 96 
Heterogeneous 1 8 9 
Total 85 20 105 
 
Pearson Chi square value- 0.0, significant 
Appearance of the endometrium is statistically significant in detecting endometrial 
abnormality 
 
Accuracy of heterogeneous appearance in endometrial abnormality 
HPE 
Appearance 
Endometrial 
disease 
No endometrial 
disease 
Total 
Present 8 1 9 
Absent 12 84 96 
Total 20 85 105 
 
 
 
Sensitivity: 40% PPV: 88.9% 
Specificity: 98.8% NPV: 87.5 % 
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Table 14: Comparison of characteristic feature & margin of endometrium  
                  with histopathology 
HPE
Characteristics & margin 
Normal Abnormal Total 
Thin line 31 - 31 
Diffuse/regular margin 52 11 63 
Diffuse/irregular margin 1 7 8 
Focal/regular margin 1 2 3 
Focal/irregular margin - - - 
Total 85 20 105 
 
Pearson Chi square value- 0.0, significant 
Thin line, diffuse with regular margin – normal  
Diffuse with irregular margin, Focal with regular margin, Focal with irregular 
margin were abnormal 
Accuracy of characteristic feature & margin in detecting endometrial 
abnormality 
HPE 
Characteristics 
Endometrial 
disease 
No endometrial 
disease 
Total 
Present  9 2 11 
Absent 11 83 94 
Total 20 85 105 
Sensitivity: 45%, PPV: 81.8%, Specificity: 97.6%, NPV: 88.3% 
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Table 15: Comparison of endometrial halo with histopathology 
                       HPE
Endometrial halo 
Normal Abnormal Total 
Present 84 13 97 
Absent 1 7 8 
Total 85 20 105 
 
Pearson Chi square value- 0.0, significant 
Endometrial halo was significantly associated with endometrial abnormality 
 
Accuracy of endometrial halo in detecting endometrial abnormality 
HPE
Endometrial halo 
Endometrial 
disease 
No endometrial 
disease 
Total 
Absent 7 1 8 
Present 13 84 97 
Total 20 85 105 
 
Sensitivity: 53.8%, PPV: 87.5% 
Specificity: 98.8%, NPV: 86.6% 
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Table 16: Comparison of endometrial thickness with histopathology in  
                 patients with symptom (post menopausal bleeding) 
HPE
 
Endometrial  
thickness 
Normal Abnormal Total 
<5 mm 30 - 30 
<10mm 17 5 22 
>10mm 5 13 18 
Total 52 18 70 
 
P value- 0.0, significant 
 
There is significant association between endometrial disease and endometrial 
thickness in women with post menopausal bleeding. 
 
Endometrial thickness > 5 mm to define abnormality in PMB 
        HPE
Endometrial  
thickness   
Endometrial 
disease 
No endometrial 
disease 
Total 
Positive TVS 18 22 40 
Negative TVS 0 30 30 
Total 18 52 70 
 
Sensitivity: 100%, PPV: 45% 
Specificity: 57.7%, NPV: 100% 
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Endometrial thickness > 10 mm cut off in women with PMB to define 
abnormality 
HPE
Endometrial  
thickness 
Endometrial 
disease 
No endometrial 
disease 
total 
Positive TVS 13 5 18 
Negative TVS 5 47 52 
Total 18 52 70 
 
Sensitivity: 72.2%, PPV: 72.2% 
Specificity: 90.4%, NPV: 90.4% 
  
43
Table 17: Comparison of endometrial thickness with histopathology in  
                 patients without symptoms 
HPE
Endometrial  
thickness 
Normal Abnormal Total 
<10mm 30 1 31 
>10mm 3 1 4 
Total 33 2 35 
 
P value- 0.077, not significant 
The endometrial thickness is not statistically associated with endometrial thickness 
in postmenopausal women without bleeding. 
 
Endometrial thickness > 10 mm cut off in women without PMB to define 
abnormality 
        HPE
Endometrial  
thickness 
Endometrial 
disease 
No endometrial 
disease 
Total 
Positive TVS 1 3 4 
Negative TVS 1 30 31 
Total 2 33 35 
 
Sensitivity: 50%, PPV: 25% 
Specificity: 90.9%, NPV: 96.8% 
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Table 18: Comparison of TVS with histopathology 
HPE diagnosis 
 
TVS diagnosis 
Atropic 
endometrium 
Carcinoma 
endometrium 
Proliferative/ 
secretory 
endometrium 
Endometrial 
polyp 
Endometrial 
hyperplasia 
Total 
Atropic endometrium 
26 - 5 - - 31 
Carcinoma 
endometrium 
- 6 1 - 1 8 
Endometrial 
Hyperplasia 
1 - 7 3 4 15 
Thickened 
endometrium 
23 1 21 1 2 48 
Endometrial polyp - - 1 - 2 3 
Total 50 7 35 4 9 105 
  
45
TVS detected 6 cases of endometrial carcinoma correctly, one was a complex 
hyperplasia and only 1 case was over diagnosed as it turned out to benign non 
pathological finding. 
One case of endometrial carcinoma was missed and was diagnosed thickened 
endometrium. 
4 cases of endometrial hyperplasia were detected co relating with HPE but over 
diagnosed 7 cases of normal endometrium. 
2 cases of hyperplasia were missed and were detected as thickened endometrium. 
None of the endometrial polyps were identified correctly on TVS. 
 3 cases of endometrial polyp were detected as hyperplasia and one as thickened 
endometrium. 
2 cases detected as polyp were in fact hyperplasia of endometrium. 
Of the 50 cases of endometrial atrophy 26 cases of atrophic endometrium were 
diagnosed by TVS. 
In a total of 48 cases with thickened endometrium 23 cases designated as 
thickened in TVS were atrophic on HPE. 
21 cases of thickened endometrium had benign normal histopathological finding. 
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Accuracy of diagnosis of endometrial abnormality in TVS 
HPE
TVS diagnosis 
Endometrial 
disease 
No endometrial 
disease 
Total 
Positive TVS 16 10 26 
Negative TVS 4 75 79 
Total 20 85 105 
 
Sensitivity 80% , Positive Predictive Value 61.54% 
Specificity 88.24%, Negative Predictive Value 94.94% 
Diagnostic Accuracy 86.67%   
 
Table 19: Accuracy of diagnosis in women with PMB by TVS 
HPE 
TVS diagnosis 
Endometrial 
disease 
No endometrial 
disease 
Total 
Positive TVS 15 6 21 
Negative TVS 3 46 49 
Total 18 52 70 
 
Sensitivity: 83.3%, PPV: 71.4% 
Specificity: 88.5%, NPV: 93.9% 
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Table 20: Accuracy of diagnosis in women without PMB 
HPE 
TVS diagnosis 
Endometrial 
disease 
No endometrial 
disease 
Total 
Positive TVS 1 4 5 
Negative TVS 1 29 30 
Total 2 33 35 
 
Sensitivity: 50%, PPV: 20% 
Specificity: 87.9%, NPV: 96.7% 
 
Table 21:  Binary logistic regression 
Variables df Significance  
Years of menopause 1 0.017 
Associated diseases 4 0.221 
Postmenopausal bleeding 1 0.012 
Appearance 1 0.217 
Characteristic feature and margin 3 0.781 
Endometrial halo 1 0.997 
Endometrial thickness 2 0.84 
 
There was strong association between postmenopausal bleeding significance-0.012 
Years of menopause significance-0.017. 
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DISCUSSION 
 
The study was a prospective descriptive study. 
 Most of the women belonged to 46 to 50 yrs of age with the range of 
age distribution between 42 to 73 yrs.  
 Women of all parity were represented in the study. 
 Majority of the patients had attained menopause within 1 to 5 years at 
the time of the study. The distribution range was between 1 to 26 years. 
 32.5% had associated co-morbid disease. 39 women were obese. 
 66.7% of the study group had postmenopausal bleeding and the rest 
were asymptomatic. 
 Abnormal findings like endometrial carcinoma, polyp, and hyperplasia 
were detected in 22.9% of the women by TVS and in 19 % of women 
by histopathology. 
 Factors like age, years of menopause, co- morbid diseases, obesity and 
postmenopausal bleeding were analysed with the histopathology of the 
endometrium. There was statistically significant association between 
postmenopausal bleeding (p <0.05), years of menopause (p <0.05) and 
the presence of co morbid diseases (p < 0.01) using the chi-square test. 
 The study by Gull B et al (2001) reported that several risk factors 
including hypertension and diabetes was associated with increased 
endometrial thickness and abnormality (44). 
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 BMI and endometrial disease had no co relation in this study. Studies by 
Guven MA et al in 2004 (48) and van den Bosch T et al (45) have 
shown no association between endometrial abnormality and BMI. 
 Binary logistic regression was used to identify the association of risk 
factors and endometrial abnormality. It had strong association in the 
presence of post menopausal bleeding and with advancing years of 
menopause. 
 In the study done by Thomas Gredmark et al (43) the occurrence of 
PMB decreased with increasing age but the probability of cancer as the 
underlying cause increased with age. The peak incidence of endometrial 
carcinoma was found in women between 65 and 69 years of age. Also a 
histopathological finding of endometrial adenomatous hyperplasia or 
cancer was seen in about 15% of the postmenopausal women with 
bleeding, which justifies a thorough examination in these women.  
 Trans vaginal ultrasound parameters take into consideration were 
appearance of the endometrial stripe (homogenous /heterogeneous), 
characteristic feature (diffuse/focal), margin (regular/irregular), 
endometrial halo (present/absent). All of them were found to 
statistically significant (p <0.01) 
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     The following observations were made: 
TVS parameters Sensitivity Specificity PPV NPV 
Heterogeneous 
appearance 
40% 98.8% 87.5% 87.5% 
Characteristic feature 
and margin 
45% 97.6% 81.8% 88.3% 
Endometrial halo 53.8% 98.8% 87.5% 86.6% 
 
 The morphological features on TVS had a high specificity, positive 
predictive value and negative predictive value but an overall low 
sensitivity. 
 Texture analysis of endometrium by G Michail et al (2007) (49) by gray 
scale ultrasound was to investigate the feasibility of texture analysis in 
characterising endometrial tissue as depicted in two-dimensional (2D) 
grayscale transvaginal ultrasonography in peri and postmenopausal 
women. The study analysed endometrium, endometrium plus adjacent 
myometrium, layer containing endometrial–myometrial interface using 
logistic regression model. Their results showed that TVS images can 
effectively differentiate malignant from benign endometrial tissue 
providing 86.0% specificity at 93.3% sensitivity using the cut-off level 
of 0.5 for probability of malignancy.  
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 Morphological changes in the endometrium have a high specificity and 
can be used reliably in the exclusion of abnormal endometrial findings 
but further investigation is needed in diagnosis of the disease. 
 
Endometrial thickness Sensitivity Specificity PPV NPV 
With PMB     
> 5 mm  100 57.7 45 100 
> 10 mm 72.2 90.4 72.2 90.4 
Without PMB 
> 10 mm  
50 90.9 25 96.8 
 
 In women with PMB there was significant association (p<0.01) with 
endometrial thickness but there was no significant association in women 
without symptoms. 
 In patients with PMB a 5 mm cut off had 100% sensitivity but low 
specificity whereas when the cut off was increased to 10 mm sensitivity 
was reduced to 72.2% but increases specificity to 90.4%.  
 This shows that a 5 mm cut off is highly accurate in excluding 
endometrial disease in PMB. As per the Compendium of Selected 
Publications by ACOG it recommends that if the endometrium is thin 
by TVS, most commonly defined as a thickness of ≤ 5 mm, the risk of 
cancer is sufficiently low that a biopsy may be deferred (22). 
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 In women with PMB when endometrium at 10 mm is considered normal 
the sensitivity and PPV is decreased to 72.2%.PMB is a strong risk 
factor for carcinoma and there is an increased probability of missing the 
diagnosis.  
 A 10 mm cut off is acceptable in women without any symptoms with a 
high  NPV of 96.8%. R. Smith Bindman et al (2004) under took a study 
to determine an endometrial thickness threshold that should prompt 
biopsy in a postmenopausal woman without vaginal bleeding. An  
11 mm threshold yields a separation between those who are at high risk 
and those who are at low risk for endometrial cancer. In postmenopausal 
women without vaginal bleeding, the risk of cancer is approximately 
6.7% if the endometrium is thick (> 11 mm) and 0.002% if the 
endometrium is thin suggesting that only at an 11 mm cut off in 
postmenopausal women without bleeding warrants the need for  
biopsy (46). 
 Of note is the high proportion of patients falling in the 5–10 mm 
"grey zone" group. In the results the greater the endometrial 
thickness, the higher the incidence of endometrial cancer is present. 
 
 The diagnosis by TVS in the study had 80% sensitivity, 88.2% 
specificity, 61.5% PPV, 94.4% NPV. The overall diagnostic accuracy in 
the study was 86.67%. Diaa El Mowafi et al (50) in the study of TVS 
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and hysteroscopy versus histopathology in postmenopausal women have 
shown sensitivity 73.9%, specificity 73.7%, PPV 77.3% and NPV 70%. 
The diagnostic accuracy was 73.4% 
 
 TVS was able to detect 6 cases of carcinoma accurately and the 
diagnosis was missed in one case only. 
 The diagnosis of polyp was missed by TVS and it might be increased by 
Saline Infusion Sonohysterography (SIS). Erdem M et al (51) in the 
study of TVS with SIS have demonstrated that the sensitivity and 
specificity of SIS in the diagnosis of endometrial polyps were 100% and 
91.8%, respectively. 
 There were differences in the identification of benign conditions. All 
types of endometrial hyperplasia (cystic, adenomatous, atypical) can 
cause diffusely smooth or, less commonly, focal hyperechoic 
endometrial thickening. (30)  
 The study showed 83.3% sensitivity, 88.5% specificity, 71.1% PPV and 
93.9% NPV in the diagnosis in women with PMB. When thickness 
alone was taken at a 5 mm cut off the values were 100%, 57.7%, 45% 
and 100%.  B. Randelzhofer et al (55) in a study analyzed various 
sonomorphological criteria prospectively in 321 women. Using the cut-
off point of 0.1 for the probability of endometrial malignancy, the 
sensitivity and specificity were 96.8% and 61.9%, respectively, with an 
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accuracy of 72.3%. In contrast, the differentiation by endometrial 
thickness as the sole criterion (cut-off point 5 mm) achieved a 
sensitivity of 97.9% and a specificity of 33.2%, with an accuracy of 
52.3%. The combination of thickness with morphological features can 
be used in the diagnosis of benign and malignant endometrial disease 
with considerable accuracy in women with postmenopausal bleeding 
 The use of TVS in the routine screening of postmenopausal women for 
endometrial disease is questionable when asymptomatic with a very low 
sensitivity (50%) and PPV (20%) though there was a high NPV 
(96.7%).B Greber et al(2001) in their study (56) aimed to investigate 
whether endometrial carcinoma screening by transvaginal sonography 
has a prognostic advantage over symptomatic women. They established 
that endometrial screening often results in unnecessary operations, 
which are associated with increased morbidity and costs. PMB was 
significantly associated with carcinoma. The bleeding time of 
symptomatic patients strongly correlated with the tumour stage. There is 
no prognostic advantage for screened compared with symptomatic 
patients. 
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SUMMARY 
 
¾ A total of 105 postmenopausal women were involved in the study 
carried out from April 2008 to September 2009 at the Institute of 
Obstetrics and Gynaecology, MMC. 
¾ TVS was done followed by histopathological diagnosis was made which 
was considered the gold standard. 
¾ Age of women ranged from 42 to 73 years with 45% between 50 to 60 
years. 
¾ Most of the women were within 10 years of attaining menopause. 
¾ A total of 30.5% had associated diseases such as hypertension, diabetes 
and other carcinomas which were significantly associated with 
endometrial disease. 
¾ BMI had no relation with endometrial disease. 
¾ Of all women 66.7% had postmenopausal bleeding and the rest were 
asymptomatic. 
¾ Postmenopausal bleeding and years of menopause had strong 
association with endometrial disease. 
¾ Morphological features including the appearance, characteristics, 
margins, endometrial halo and endometrial thickness produced 
significant association with endometrial disease. 
¾ The overall diagnostic accuracy of TVS was 86.7%. 
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¾ The overall sensitivity, specificity, positive predictive value and 
negative predictive values were 80.0%, 88.2%, 61.5% and 94.9%. 
¾ The accuracy of diagnosis was better in women with postmenopausal 
bleeding than those without bleeding. 
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CONCLUSIONS 
 
9 Transvaginal sonography is safe, simple, non invasive and cost 
effective in the diagnosis of endometrial disease. 
9 It can be used as the first line investigation in women with 
postmenopausal bleeding. 
9 A lesion if considered abnormal or suspicious can be further 
investigated and the mode of investigation can be decided based on 
findings. 
9  Use of saline infusion sonohysterography along with TVS can 
increase the accuracy of findings especially in diagnosing 
endometrial polyps. 
9 The combination of morphological features with endometrial 
thickness on gray scale ultrasound increases the diagnostic 
accuracy than with endometrial thickness alone. 
9 The routine use of TVS for screening of endometrial disease is not 
useful in postmenopausal women.  
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PROFORMA 
 
 
Name:                                                 Age:                       IP number: 
 
Occupation:                                                    Socioeconomic status: 
 
Residential Address: 
 
Age at menopause: 
 
Do you have postmenopausal bleeding?    Yes/No 
 
If Yes 
Time of onset 
Duration of bleeding 
Pattern of bleeding 
Amount of bleeding 
Any history of recurrent episodes 
 
History of White discharge P/V          Yes/ No 
History of abdominal pain                  Yes/ No 
History of any post coital bleeding     Yes/ No  
History of any urinary disturbance     Yes/ No      
 
Marital history: 
Number of years since marriage: 
Parity: 
Total number of live children: 
Age at first child birth: 
Last child birth: 
Abortions if any: Spontaneous /induced 
History of any contraceptive use: Yes/No 
If Yes- OCP/Intra uterine device/ barrier Methods/ Injectable or implant 
hormones/ tubectomy 
 
Menstrual History: 
Age at menarche: 
Total number of years after menopause: 
Nature of menopause- Gradual/ Stormy 
History of any hormone replacement therapy: Yes/ No 
If yes – number of years used/ using 
             Type of HRT 
             Indication 
History of previous cycles: Regular/irregular 
                                             Length of cycles 
                                           
Past History: 
History of Any medical illness: 
Essential Hypertension/ Diabetes mellitus/ Bronchial asthma/ Thyroid disorders/ 
Epilepsy/ Heart disease/ Tuberculosis/ bleeding disorders 
If others specify: 
Duration of disease: 
Treatment taken: 
History of carcinoma: Yes/No 
If yes- Site  
           Type 
           Mode of treatment 
History of surgeries in the past: Yes/ No 
If yes- Type of surgery and indication 
 
Family history: 
History of Ovarian/ endometrial/ cervical/ Breast/ Gastrointestinal malignancies 
If any others, specify 
 
General examination: 
 
Build:                                              Nourishment: 
 
Height:                                   Weight:                                 BMI: 
 
Pulse rate:                    Blood Pressure: 
 
Pallor/ Pedal edema/ Lymphadenopathy/ Clubbing 
 
Thyroid and Breast examination: 
 
Cardiovascular System:                                   Respiratory System: 
    
Per abdomen examination: 
 
Local examination: 
 
Per speculum examination: 
 
Per vaginal examination: 
 
Investigations: 
• Urine routine 
• Complete Haemogram 
• Blood sugar 
• Blood Urea 
• Serum Creatinine 
• Electrocardiogram(ECG) 
• Chest X-ray PA view 
• Trans vaginal Ultrasonography 
• Trans abdominal ultrasound 
• Endometrial histopathology 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
 
             PMB- Postmenopausal bleeding 
             TVS- Transvaginal sonography 
             USG- Ultrasonography 
             TAS- Transabdominal sonography 
             MRI-Magnetic resonance imaging 
             PPV- Positive predictive value 
             NPV- Negative predictive value 
             SIS- Saline infusion sonohysterography 
             BMI- Basal metabolic index 
             HPE- Histopathological examination 
             HRT-Hormone replacement therapy 
   CT- Computed Tomography 
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 S.no NAME AGE IP no MENOPAUSE DISEASE PARITY BLEEDING BMI EM THICKNESS APPERANCE CHARECTERISTIC Endometrial Halo DIAGNOSIS HPE
1 Elizabeth 48 16816 1 nil 2 yes >25 5 homogenous diffuse, regular yes thick proliferative
2 Datchayini 49 6506 3 nil 2 no <25 28 homogenous focal, regular yes polyp proliferative
3 Chandra 60 16533 15 nil 7 yes <25 1 homogenous thin line yes atrophic atrophic
4 Subulakshmi 48 16791 3 nil 5 yes <25 2 homogenous thin line yes atrophic proliferative
5 Kausalya 70 6521 20 HT 5 yes >25 10 homogenous diffuse, regular yes hyperplasia simple hyperplasia
6 Lakshmi 60 3023 20 HT 7 no <25 5 homogenous diffuse,regular yes thick atrophic
7 Esther 65 4863 17 nil 6 yes <25 1 homogenous thin line yes atrophic atrophic
8 Thangama 70 4292 20 nil 0 yes >25 3 homogenous thin line yes atrophic atrophic
9 Vennila 50 1291 1 nil 2 yes <25 5 homogenous diffuse, regular yes thick atrophic
10 Gowri 48 7863 2 nil 3 yes <25 5 homogenous thin line yes atrophic atrophic
11 Vasantha 45 7846 2 nil 2 yes >25 7 homogenous diffuse, regular yes thick proliferative
12 Vasantha 58 7999 16 HT 3 yes <25 18 homogenous focal, regular yes polyp simple hyperplasia
13 Saratha 51 5567 5 nil 2 no <25 5 homogenous diffuse, regular yes thick atrophic
14 Padmavathy 49 5184 1 nil 4 yes <25 3 homogenous thin line yes atrophic proliferative
15 Kuppama 53 5561 4.5  HT & DM 3 yes >25 11 heterogenous diffuse, irregular margin no a endometriu Ca endometrium Ic
16 Devakirbamani 52 9168 2 nil 3 yes <25 4 homogenous thin line yes atrophic atrophic
17 Apoorvam 52 15525 4 nil 4 no <25 5 homogenous diffuse, regular yes thick atrophic
18 Lakshmi 45 14813 8 nil 3 yes >25 6 homogenous diffuse,irregular no a endometriu Ca endometrium Ic
19 Prema 44 16724 1 DM & anaemia 4 yes <25 5 homogenous diffuse, regular yes thick proliferative
20 Kasthuri 55 16316 15 DM 4 yes <25 9 homogenous diffuse, regular yes thick polyp
21 Kumari 45 17155 1 DM 4 yes >25 8 homogenous diffuse, regular yes thick complex hyperplasia
22 Noor Bee 59 14109 12 HT & DM 6 yes >25 9.5 heterogenous diffuse,irregular yes a endometriu comp hyperplasia atypia
23 Rangamma 53 14075 7 nil 3 yes <25 1 homogenous thin line yes atrophic atrophic
24 Saraswathy 55 13069 10 nil 5 no >25 5 homogenous diffuse, regular yes thick senile cystic atrophy
25 Saratha 50 8069 1 DM 5 yes >25 10 homogenous diffuse, regular yes hyperplasia simple hyperplasia
26 Vasanthi 50 9379 1.5 nil 2 yes <25 3 homogenous thin line yes atrophic atrophic
27 Vasantha 46 19338 1 nil 3 yes <25 9 homogenous diffuse, regular yes thick secretory
28 Senthamariamma 70 19306 26 nil 1 yes <25 3 homogenous thin line yes atrophic atrophic
29 Ammaniammal 55 16774 10 nil 5 no <25 6 homogenous diffuse, regular yes thick atrophic
30 Lakshmi 57 19354 11 Ca caecum 2 yes <25 15 heterogenous diffuse, irregular margin no a endometriu Ca endometrium II b
31 Kumari 45 19682 1 nil 3 yes <25 3 homogenous thin line yes atrophic proliferative
32 Varalakshmi 55 17777 2 HT & DM 3 yes >25 3 homogenous thin line yes atrophic atrophic
33 Chellamma 46 6814 5 nil 1 no <25 5 homogenous diffuse, regular yes thick atrophic
34 sulochana 50 1598 9 nil 3 no <25 7 homogenous diffuse, regular yes thick proliferative
35 Akilandam 50 15224 1 nil 3 yes <25 2 homogenous thin line yes atrophic proliferative
36 Saroja 50 12954 3 nil 4 no <25 6 homogenous diffuse, regular yes thick atrophic
37 Nagammal 50 13575 5 nil 2 no >25 7 homogenous diffuse,regular yes thick atrophic
38 Suriyagandhi 55 10524 15 HT 2 yes >25 6 homogenous diffuse, regular yes thick senile cystic atrophy
39 Rani 51 11111 1 nil 3 no <25 7 homogenous diffuse, regular yes thick simple hyperplasia
40 Chandra 55 12637 10 nil 4 yes <25 2 homogenous thin line yes atrophic atrophic
41 Subheda bee 58 10203 6 HT 7 yes >25 3 homogenous thin line yes atrophic atrophic
42 Manimegalai 45 12023 1 nil 2 no <25 7 homogenous diffuse, regular yes thick proliferative
43 Rajalakshmi 57 6924 5 HT 3 yes >25 15 heterogenous diffuse, irregular margin no a endometriu Ca endometrium IIa
44 Nirmala 63 27889 16 nil 4 no <25 5 homogenous diffuse, regular yes thick atrophic
45 Krishnaveni 60 29475 10 nil 2 no >25 6 homogenous diffuse, regular yes thick atrophic
46 Bagyalakshmi 58 28461 1 nil 2 yes >25 8 homogenous diffuse, regular yes thick proliferative
47 Pachiammal 45 30671 1 nil 4 yes <25 10 homogenous diffuse, regular yes hyperplasia proliferative
48 Govindamma 45 30672 1 nil 3 yes <25 4 homogenous thin line yes atrophic proliferative
49 Jakubai 50 6712 1.5 nil 4 yes <25 4 homogenous thin line yes atrophic atrophic
50 Ammni 48 21164 7 nil 3 no <25 5 homogenous diffuse, regular yes thick proliferative
51 Thenjaiamma 55 20594 4 nil 4 no <25 6 homogenous diffuse, regular yes thick senile cystic atrophy
52 Prema 48 30922 1 nil 4 yes <25 10 homogenous diffuse, regular yes hyperplasia proliferative
53 Kasiammal 51 30321 3 HT 3 yes >25 8 homogenous diffuse, regular yes thick proliferative
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54 Maragatham 50 30321 2 nil 0 yes >25 17 homogenous diffuse, regular no hyperplasia polyp
55 Mariamma 60 25168 5 nil 1 no <25 8 homogenous diffuse, regular yes thick senile cystic atrophy
56 Karpagam 55 23430 10 DM 3 yes <25  2 homogenous thin line yes atrophic atrophic
57 Aryammal 50 17385 4 nil 3 no <25 11 heterogenous diffuse, irregular margin no a endometriu proliferative
58 Pushpa 56 17747 12 nil 3 no >25 5 homogenous diffuse, regular yes thick senile cystic atrophy
59 Bhaskaravalli 49 17446 1 nil 3 yes >25 8 homogenous diffuse, regular yes thick proliferative
60 Valliammal 55 17732 10 nil 4 no <25 5 homogenous diffuse, regular yes thick atrophic
61 Sowbhagyam 42 16432 1 nil 1 yes >25 7 heterogenous focal, regular yes polyp comp hyperplasia atypia
62 Devi 50 23562 1 DM 4 no <25 8 homogenous diffuse, regular yes thick proliferative
63 Rajeshwari 55 23811 10 nil 4 yes <25 4 homogenous thin line yes atrophic atrophic
64 Nageshwari 53 16154 1 HT 1 yes >25 20 heterogenous diffuse, irregular margin no a endometriu Ca endometrium IIa
65 Shanti 58 16814 10 nil 3 yes >25 16 homogenous diffuse, regular yes hyperplasia proliferative
66 Grace 55 16623 3 HT 4 yes >25 7 homogenous diffuse, regular yes thick atrophic
67 Munniamma 60 18368 8 HT 3 yes >25 12 heterogenous diffuse, irregular margin no a endometriu Ca endometrium IIb
68 Chinathai 55 14179 1 nil 3 yes <25 7 homogenous diffuse, regular yes thick proliferative
69 Selvi 47 18374 2 nil 5 no <25 7 homogenous diffuse, regular yes thick secretory
70 Shahida 48 18595 1 nil 4 no >25 5 homogenous diffuse, regular yes thick proliferative
71 Kalaivani 52 17733 9 HT 3 yes >25 10 homogenous diffuse, regular yes hyperplasia proliferative
72 Chaitini 58 17581 15 nil 3 yes <25 6 homogenous diffuse, regular yes thick Ca endometrium Ic
73 Mala 43 17819 1 DM 3 yes <25 4 homogenous thin line yes atrophic atrophic
74 Stella 52 17829 10 HT 5 yes >25 4 homogenous thin line yes atrophic atrophic
75 Unnamalai 45 17909 6 nil 3 no <25 6 homogenous diffuse, regular yes thick atrophic
76 Asmath 55 11997 10 DM 4 no >25 5 homogenous diffuse, regular yes thick proliferative
77 Anjammal 50 19953 1.5 nil 3 yes <25 5 homogenous diffuse, regular yes thick proliferative
78 Devakirba 53 11254 2 nil 2 yes <25 7 homogenous diffuse, regular yes thick proliferative
79 Valarmathy 48 8623 1 nil 3 yes <25 6 homogenous diffuse, regular yes thick proliferative
80 Kamala 55 11566 4 nil 3 no <25 5 homogenous diffuse, regular yes thick atrophic
81 Padmalayam 73 12158 20 Breast ca 4 no <25 14 homogenous diffuse, regular yes hyperplasia simple hyperplasia
82 Achikannu 50 14351 3 nil 4 yes >25 8 homogenous diffuse, regular yes thick proliferative
83 Mariammal 55 8654 8 nil 0 yes <25 12 heterogenous diffuse, regular yes hyperplasia polyp
84 Pavalakodi 60 16211 5 nil 4 yes <25 4 homogenous thin line yes atrophic atrophic
85 Amul 45 8690 2 nil 2 yes <25 4 homogenous thin line yes atrophic atrophic
86 Saroja 50 8867 10 nil 5 yes >25 4 homogenous thin line yes atrophic atrophic
87 Meena 60 13456 6 nil 2 no >25 6 homogenous diffuse, regular yes thick atrophic
88 Elakkal 70 4536 18 nil 4 yes >25 2 homogenous thin line yes atrophic atrophic
89 Munniammal 49 3245 3 HT 5 no <25 9 homogenous diffuse, regular yes thick proliferative
90 Santha 45 1785 2 DM 3 no <25 6 homogenous diffuse, regular yes thick proliferative
91 Sivapoosam 53 1876 1 HT & DM 4 yes <25 14 homogenous diffuse, regular yes hyperplasia complex hyperplasia
92 Radha 48 2345 3 nil 3 no >25 7 homogenous diffuse, regular yes thick proliferative
93 Visalakshi 50 7654 7 nil 2 yes >25 3 homogenous thin line yes atrophic atrophic
94 Anthoniammal 46 8765 2 nil 5 no <25 5 homogenous diffuse, regular yes thick atrophic
95 Fariza Banu 56 5674 12 DM 7 yes >25 2 homogenous thin line yes atrophic atrophic
96 Kuppu 45 14321 2 nil 5 yes <25 10 homogenous diffuse, regular yes hyperplasia proliferative
97 Rajathi 60 12365 15 HT 4 yes <25 13 homogenous diffuse, regular yes hyperplasia polyp
98 Ganga 53 5643 1.5 nil 1 no <25 5 homogenous diffuse , regular yes thick senile cystic atrophy
99 Thanalakshmi 48 7654 4 nil 3 yes <25 3 homogenous thin line yes atrophic atrophic
100 Jayamma 65 8452 12 HT 6 yes <25 4 homogenous thin line yes atrophic senile cystic atrophy
101 Rani 62 6719 10 nil 0 yes <25 7 homogenous diffuse, regular yes thick atrophic
102 Barani 46 12867 2 nil 2 no >25 11 homogenous diffuse, regular yes hyperplasia proliferative
103 Sarasu 51 8790 2 nil 4 yes >25 3 homogenous thin line yes atrophic atrophic
104 Kaveri 47 9231 3 nil 5 no <25 6 homogenous diffuse, regular yes thick atrophic
105 Janakiammal 59 15321 9 nil 6 yes <25 4 homogenous thin line yes atrophic atrophic
